A Study of ILB2109 in Patients With Advanced Solid Malignancies

NCT05278546 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: ILB2109

Sponsor

Innolake Biopharm

Collaborators

[object Object]
[object Object]